Cantor Fitzgerald Reiterates Overweight on Enovix, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 73.1%

Neg 0% Neu 73.1% Pos 0%

Cantor Fitzgerald analyst Derek Soderberg reiterates Enovix (NASDAQ:ENVX) with a Overweight and maintains $25 price target.